October 28th, 2026Derm Dispatch: Rethinking Dermoscopy Training to Improve Melanoma DetectionA melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve early melanoma detection.Read more
October 28th, 2026How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment LandscapeAtopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.Read more
October 27th, 2026FDA Revises TB Evaluation Guidance for SKYRIZIUpdated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.Read more
October 27th, 2026Avoiding Common Mistakes When Escalating Therapy in PsoriasisExperts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.Read more
October 27th, 2026ATI-052 Shows Rapid Improvements in Atopic DermatitisATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.Read more
October 26th, 2026FDA Accepts IND for Injectable rhPDGF-BB in Under-Eye HollowingLRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.Read more
October 26th, 2026ORKA-001 Achieves 61% Complete Skin Clearance in PsoriasisORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.Read more
October 25th, 2026Dermatology Times Spot Test: October 25, 2026Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.Read more